Efficacy of rituximab in refractory neuromyelitis optica-Reference-Cited by-同舟云学术

Efficacy of rituximab in refractory neuromyelitis optica

Published:2015-09-11 Issue:7 Volume:22 Page:955-959
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Collongues N¹,Brassat D²,Maillart E³,Labauge P⁴,Ouallet JC⁵,Carra-Dalliere C⁴,Moreau T⁶,Bourre B⁷,Papeix C³,Brochet B⁵,Audoin B⁸,Vukusic S⁹,de Seze J¹,Marignier R⁹,

Affiliation:

1. Department of Neurology, Hopital de Hautepierre, France

2. Department of Neurology, Hopital Purpan, France

3. Department of Neurology, Hopital Pitie-Salpetriere, France

4. Department of Neurology, Hopital Universitaire de Montpellier, France

5. Department of Neurology, Centre Hospitalier Universitaire de Bordeaux, France

6. Department of Neurology, Hopital Universitaire de Dijon, France

7. Department of Neurology, Hopital Charles Nicolle, France

8. Department of Neurology, Hopital Universitaire de Marseille, France

9. Department of neurology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France

Abstract

Background: Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy. Objective: The purpose of this study was to assess RTX as a maintenance therapy in RNMO. Methods: Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months. Results: After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 ( p<0.001) and median EDSS from 5 to 3 ( p=0.02). Body mass index (BMI) was predictive of EDSS worsening. Conclusions: RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458515602337

Reference11 articles.

1. Impact of rituximab on relapse rate and disability in neuromyelitis optica

2. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success

3. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders

4. Treatment of Neuromyelitis Optica With Rituximab

5. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies;Revue Neurologique;2024-03

2. Neuromyelitis optic spectrum disorders (NMOSD): from pathogenesis to targeted therapy;Neurology, Neuropsychiatry, Psychosomatics;2023-08-21

3. A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder;Current Neurology and Neuroscience Reports;2023-08-04

4. Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder;Neurology;2023-07-25

5. Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort;Journal of Neurology;2022-12-24